Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + AK105 in Advanced Gastrointestinal, Genitourinary and Neuroendocrine Tumors
CTR20192554Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA), gallbladder cancer, colorectal cancer (CRC), gastric adenocarcinoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Mar 2020; status: terminated.
02
Drugs
penpulimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancercolorectal cancer (CRC)gastric adenocarcinoma
Beyond the preview
Go deeper on CTR20192554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192554.